Sanofi Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sanofi wird ein jährliches Gewinn- und Umsatzwachstum von 17.9% bzw. 5.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.1% betragen.

Wichtige Informationen

17.9%

Wachstumsrate der Gewinne

18.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	5.3%
Zukünftige Eigenkapitalrendite	14.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sep 10

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Aug 17

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:SAN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	53,062	9,805	10,010	N/A	15
12/31/2025	49,934	9,462	9,054	N/A	16
12/31/2024	46,338	6,855	7,142	N/A	14
9/30/2024	48,445	4,506	N/A	N/A	N/A
6/30/2024	47,080	4,216	4,138	8,118	N/A
3/31/2024	46,288	4,538	N/A	N/A	N/A
12/31/2023	46,033	5,400	7,234	10,258	N/A
9/30/2023	45,699	9,066	N/A	N/A	N/A
6/30/2023	46,045	8,617	8,107	10,264	N/A
3/31/2023	46,199	8,357	N/A	N/A	N/A
12/31/2022	45,389	8,371	8,325	10,526	N/A
9/30/2022	44,348	6,409	N/A	N/A	N/A
6/30/2022	42,039	6,643	7,594	9,620	N/A
3/31/2022	40,342	6,666	N/A	N/A	N/A
12/31/2021	39,175	6,223	8,479	10,522	N/A
9/30/2021	38,496	6,174	N/A	N/A	N/A
6/30/2021	37,546	5,777	5,827	8,219	N/A
3/31/2021	36,939	12,197	N/A	N/A	N/A
12/31/2020	37,369	12,294	5,335	7,418	N/A
9/30/2020	37,650	11,224	N/A	N/A	N/A
6/30/2020	37,692	11,138	6,834	8,491	N/A
3/31/2020	38,234	3,453	N/A	N/A	N/A
12/31/2019	37,631	2,855	5,928	7,715	N/A
9/30/2019	36,940	3,179	N/A	N/A	N/A
6/30/2019	36,763	3,591	4,958	6,953	N/A
3/31/2019	36,264	4,439	N/A	N/A	N/A
12/31/2018	35,677	4,319	3,570	5,547	N/A
9/30/2018	35,316	4,041	N/A	N/A	N/A
6/30/2018	34,985	3,243	N/A	6,596	N/A
3/31/2018	35,428	3,539	N/A	N/A	N/A
12/31/2017	36,221	3,773	N/A	7,379	N/A
9/30/2017	36,400	4,593	N/A	N/A	N/A
6/30/2017	36,315	4,744	N/A	8,133	N/A
3/31/2017	35,677	4,682	N/A	N/A	N/A
12/31/2016	34,696	4,395	N/A	7,838	N/A
9/30/2016	34,349	4,195	N/A	N/A	N/A
6/30/2016	34,115	4,154	N/A	8,122	N/A
3/31/2016	34,569	4,440	N/A	N/A	N/A
12/31/2015	34,861	4,411	N/A	8,920	N/A
9/30/2015	37,201	5,292	N/A	N/A	N/A
6/30/2015	32,910	4,628	N/A	8,561	N/A
3/31/2015	35,074	4,329	N/A	N/A	N/A
12/31/2014	31,999	4,273	N/A	7,690	N/A
9/30/2014	33,484	4,112	N/A	N/A	N/A
6/30/2014	33,134	4,140	N/A	7,463	N/A
3/31/2014	33,074	3,812	N/A	N/A	N/A
12/31/2013	31,291	3,639	N/A	6,954	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SANDas prognostizierte Gewinnwachstum (17.9% pro Jahr) liegt über der Sparquote (1.4%).

Ertrag vs. Markt: SANDie Erträge des Unternehmens (17.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (12.5% pro Jahr).

Hohe Wachstumserträge: SANDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: SANDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.6% pro Jahr).

Hohe Wachstumseinnahmen: SANDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SANDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.1%).

Sanofi Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken